Clinical Study
Induction of Specific Immunotherapy with Hymenoptera Venoms Using Ultrarush Regimen in Children: Safety and Tolerance
Table 1
Clinical data of children undergoing ultrarush venom immunotherapy.
| | No. patients | Total 94 | Bee venom ultrarush | Wasp venom ultrarush |
| | Age in years | | | | | Range | 4.0–15.1 | | | | Mean, median | 10.4, 10.5 | | |
| | Gender | | | | | Boys | 78 (76.5 %) | 47 (46.1%) | 31 (30.4%) | | Girls | 24 (23.5 %) | 18 (17.6%) | 6 (5.9%) |
| | Allergen | | | | | Bee venom | 57 (55.9 %) | 65 (63.7%) | | | Wasp venom | 29 (28.4 %) | | 37 (36.3 %) | | Both | 8 (7.8 %) | | |
| | Grade of reaction to field sting | | | | | I | 1 (1.0%) | 1 | 0 | | II | 20 (19.6%) | 13 | 7 | | III | 60 (58.8%) | 37 | 23 | | IV | 15 (14.7%) | 9 | 6 | | Other (Sensitisation) | 6 (5.9%) | 5 | 1 |
|
|
